David S Clarke
Overview
Explore the profile of David S Clarke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
42
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scott J, Bowker S, Brocklehurst K, Brown H, Clarke D, Easter A, et al.
J Med Chem
. 2014 Oct;
57(21):8984-98.
PMID: 25286150
Agonism of GPR119 is viewed as a potential therapeutic approach for the treatment of type II diabetes and other elements of metabolic syndrome. During progression of a previously disclosed candidate...
2.
McCoull W, Barton P, Brown A, Bowker S, Cameron J, Clarke D, et al.
J Med Chem
. 2014 Jun;
57(14):6128-40.
PMID: 24967667
Ghrelin plays a major physiological role in the control of food intake, and inverse agonists of the ghrelin receptor (GHS-R1a) are widely considered to offer utility as antiobesity agents by...
3.
Scott J, Brocklehurst K, Brown H, Clarke D, Coe H, Groombridge S, et al.
Bioorg Med Chem Lett
. 2013 May;
23(11):3175-9.
PMID: 23628336
A series of conformationally restricted GPR119 agonists were prepared based around a 3,8-diazabicyclo[3.2.1]octane scaffold. Examples were found to have markedly different pharmacology in mouse and human despite similar levels of...
4.
Scott J, Birch A, Brocklehurst K, Broo A, Brown H, Butlin R, et al.
J Med Chem
. 2012 May;
55(11):5361-79.
PMID: 22545772
G protein coupled receptor 119 (GPR119) is viewed as an attractive target for the treatment of type 2 diabetes and other elements of the metabolic syndrome. During a program toward...
5.
Brocklehurst K, Broo A, Butlin R, Brown H, Clarke D, Davidsson O, et al.
Bioorg Med Chem Lett
. 2011 Nov;
21(24):7310-6.
PMID: 22061639
GPR119 is increasingly seen as an attractive target for the treatment of type II diabetes and other elements of the metabolic syndrome. During a programme aimed at developing agonists of...
6.
Pike K, Allen J, Caulkett P, Clarke D, Donald C, Fenwick M, et al.
Bioorg Med Chem Lett
. 2011 Apr;
21(11):3467-70.
PMID: 21515051
The continued optimization of a series of glucokinase activators is described, including attempts to understand the interplay between molecular structure and the composite parameter of unbound clearance. These studies resulted...
7.
Tetlow D, Hennecke U, Raftery J, Waring M, Clarke D, Clayden J
Org Lett
. 2010 Nov;
12(23):5442-5.
PMID: 21062018
On lithiation with lithium amides, N-allyl-N'-aryl ureas undergo rearrangement with transfer of the aryl ring from N to the allylic α carbon. From the α-arylated products, a further aryl transfer...
8.
Block M, Boyer S, Brailsford W, Brittain D, Carroll D, Chapman S, et al.
J Med Chem
. 2002 Jul;
45(16):3509-23.
PMID: 12139462
The hypothesis that antagonists of the neuropeptide Y5 receptor would provide safe and effective appetite suppressants for the treatment of obesity has prompted vigorous research to identify suitable compounds. We...